阻断肠肝循环在鹅膏毒肽中毒中的作用
该研究为系统评价,纳入133篇文献共1119例鹅膏毒肽中毒病例,评估阻断肠肝循环(尤其是活性炭)对患者结局和实验室指标的影响。结果显示,使用单次或多剂活性炭组生存率为83%(n=667),对照组为75%(n=452),差异有统计学意义(P<0.001,OR 1.89,95%CI 1.40-2.56)。两组丙氨酸氨基转移酶和天冬氨酸氨基转移酶峰值无差异,但活性炭组总血清胆红素和INR峰值显著降低。作者认为活性炭通过阻断肠肝循环促进鹅膏毒肽消除,可能为吸收后阶段患者提供一种安全且廉价的治疗选择。
要点
- 在1119例鹅膏毒肽中毒患者中,使用单次或多剂活性炭组生存率为83%(n=667),对照组为75%(n=452),P<0.001,OR 1.89(95%CI 1.40-2.56)。
- 活性炭组与对照组在丙氨酸氨基转移酶和天冬氨酸氨基转移酶峰值上无差异。
- 活性炭组总血清胆红素峰值和国际标准化比值(INR)峰值较对照组统计学显著降低。
- 作者认为活性炭通过阻断肠肝循环促进鹅膏毒肽消除,可能为吸收后阶段患者提供一种安全且廉价的治疗选择。
- 该结论基于病例报告和系列的系统评价,存在发表偏倚可能,且缺乏鹅膏毒肽浓度的普遍确认。
适用人群与场景
- 鹅膏毒肽中毒患者,数据来源于病例报告和系列,包括对照人群(n=452)和接受单次或多剂活性炭治疗的人群(n=667)。
处置流程与药物剂量
- 使用单次或多剂活性炭治疗鹅膏毒肽中毒患者(n=667),具体剂量、给药途径和频次原文未写明。
研究设计与关键结果
- 系统评价纳入133篇文献,共1119例独特病例;活性炭组(n=667)生存率83%,对照组(n=452)生存率75%,P<0.001,OR 1.89(95%CI 1.40-2.56)。
- 活性炭组与对照组丙氨酸氨基转移酶和天冬氨酸氨基转移酶峰值无差异。
- 活性炭组总血清胆红素峰值和国际标准化比值(INR)峰值较对照组统计学显著降低。
证据类型、等级与局限
- 证据类型:系统评价,纳入病例报告和系列。
- 局限:可能存在发表偏倚;缺乏鹅膏毒肽浓度的普遍确认;无法直接测量鹅膏毒肽的肠肝循环。
对床旁实践的改变
- 作者认为,活性炭通过阻断肠肝循环促进鹅膏毒肽消除,可能为吸收后阶段患者提供一种安全且廉价的治疗选择。
- 活性炭治疗与鹅膏毒肽中毒患者更高生存率相关(83% vs 75%),并降低总胆红素和INR峰值,但不改变转氨酶峰值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Interruption of the enterohepatic circulation is regarded as an effective way to treat patients with amatoxin poisoning. Nonetheless, its effectiveness has not yet been systematically evaluated. Therefore, we performed a systematic review to investigate the role of enterohepatic circulation on patient outcome and clinical laboratory values. We specifically sought to evaluate the effect of activated charcoal, which absorbs drugs and toxins in the gastrointestinal tract.
METHODS: A previously established database with data extracted from case reports and series from literature, supplemented with recent publications, was used. Patient characteristics, outcome, and laboratory values were evaluated.
RESULTS: We included 133 publications describing a total of 1,119 unique cases. Survival was 75 per cent in the control group (n = 452), whereas in the group treated with single or multiple doses of activated charcoal (n = 667) survival was 83 per cent (P < 0.001, odds ratio 1.89 [95 per cent confidence interval 1.40-2.56]). Furthermore, no difference in peak values of alanine aminotransferase and aspartate aminotransferase activities were observed, whereas peak values of total serum bilirubin concentration and international normalized ratio were statistically significantly reduced in patients treated with activated charcoal.
DISCUSSION: The ability of activated charcoal to enhance the elimination of amatoxin through interruption of the enterohepatic circulation offers a potentially safe and inexpensive therapy for patients in the post-absorptive phase.
LIMITATIONS: Limitations include the potential for publication bias, the lack of universal confirmation of amatoxin concentrations, and the inability to directly measure enterohepatic circulation of amatoxin.
CONCLUSION: Treatment with activated charcoal in patients with amatoxin poisoning was associated with a greater chance of a successful outcome. Additionally, activated charcoal was associated with a reduction in markers of liver function, but not markers of liver injury.
参考来源
- Varekamp J, Tan JL, Stam J, et al. Effects of interrupting the enterohepatic circulation in amatoxin intoxications. Clin Toxicol (Phila). 2024. PMID: 38411174. doi:10.1080/15563650.2024.2312182
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。